FLUMIST 2026-2027 (influenza vaccine trivalent live 2026-2027 (2 yrs-49 yrs))
INFLUENZA VACCINE · INFLUENZA VACCINATION
MEDIMMUNE/ASTRA
Drug class
Influenza Vaccine
The influenza vaccine drug class consists of immunizing biological agents formulated as inactivated, recombinant, or live-attenuated viral preparations. Read more about Influenza Vaccine
12 drugs in this class 6 manufacturers
Drugs in Influenza Vaccine
FLUMIST HOME 2026-2027 (influenza vaccine trivalent live 2026-2027 (2 yrs-49 yrs))
INFLUENZA VACCINE · INFLUENZA VACCINATION
MEDIMMUNE/ASTRA
MFLUSIVA 2026-2027 (influenza virus vacc tv 2026-27(50 yr up) mRNA/PF)
INFLUENZA VACCINE · INFLUENZA VACCINATION
MODERNA US, INC
Filter & compare in the drug finder →
Opens the drug finder with Influenza Vaccine preselected. Add indication or manufacturer filters there.
The influenza vaccine drug class consists of immunizing biological agents formulated as inactivated, recombinant, or live-attenuated viral preparations.
These vaccines stimulate active immunity by inducing the host immune system to produce neutralizing antibodies primarily targeted against the influenza hemagglutinin surface glycoprotein.
Their primary therapeutic role is the active immunization and prevention of respiratory illness and associated severe complications caused by circulating influenza A and B viruses.
Formulations are updated seasonally to align with circulating viral strains and are widely indicated for routine annual prophylaxis across pediatric, adult, and high-risk populations.
-
cdc.gov
The influenza vaccine drug class consists of immunizing biological agents formulated as inactivated, recombinant, or live-attenuated viral preparations These vaccines stimulate active immunity by inducing the host immune system to produce neutralizing antibodies primarily targeted against the influenza hemagglutinin surface glycoprotein
-
cdc.gov
These vaccines stimulate active immunity by inducing the host immune system to produce neutralizing antibodies primarily targeted against the influenza hemagglutinin surface glycoprotein
-
fda.gov
Their primary therapeutic role is the active immunization and prevention of respiratory illness and associated severe complications caused by circulating influenza A and B viruses
-
cdc.gov
Their primary therapeutic role is the active immunization and prevention of respiratory illness and associated severe complications caused by circulating influenza A and B viruses
-
fda.gov
Formulations are updated seasonally to align with circulating viral strains and are widely indicated for routine annual prophylaxis across pediatric, adult, and high-risk populations
-
nih.gov
Formulations are updated seasonally to align with circulating viral strains and are widely indicated for routine annual prophylaxis across pediatric, adult, and high-risk populations
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.